Andrew Davis
Corporate Officer/Principal at IRONWOOD PHARMACEUTICALS, INC.
Net worth: 2 M $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas McCourt | M | 66 | 15 years | |
| Julie McHugh | F | 59 | 10 years | |
| Graham Lumsden | M | 64 |
BioMarck Pharmaceuticals Ltd.
 BioMarck Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC. | 3 years |
| Rasmus Toft-Kehler | M | - |
UTILITY therapeutics Ltd.
 UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 6 years |
| Ronald Silver | M | 42 | 6 years | |
| Thomas Hadley | M | - |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 4 years |
| Jay Shepard | M | 66 | 4 years | |
| John Minardo | M | 49 | 3 years | |
| Mike Nanfito | M | - | 12 years | |
| Alexander Denner | M | 54 | 4 years | |
| Marcel Moulaison | M | - | 10 years | |
| Marla Kessler | F | 54 | 5 years | |
| Catherine Moukheibir | F | 64 | 5 years | |
| Morten Otto Sommer | M | 43 |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 6 years |
| Andrew Dreyfus | M | 65 | 8 years | |
| Peter Aksel Villadsen | M | - |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 6 years |
| Mark Currie | M | 69 | 5 years | |
| Jon Duane | M | 65 | 5 years | |
| Susanna H. Huh | M | - | 2 years | |
| Sravan Emany | M | 46 | 3 years | |
| Peter Dannenbaum | M | - | 7 years | |
| Michael Shetzline | M | 65 | 5 years | |
| Larry G. Edwards | M | 52 |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 3 years |
| Diane Stroehmann | F | 46 | 5 years | |
| Beth Calitri | F | - | 5 years | |
| Alan Roemer | M | 54 |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | 4 years |
| Dean Li | M | 62 | 7 years | |
| Greg Martini | M | - | 7 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gina Consylman | F | 52 | 7 years | |
| Jason Rickard | M | 53 | 11 years | |
| Charles Kidder | M | 79 | 12 years | |
| Lawrence Olanoff | M | 72 | 7 years | |
| Edward Owens | M | 77 | 9 years | |
| Brian Dickson | M | - |
BioMarck Pharmaceuticals Ltd.
BioMarck Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC. | - |
| John Noseworthy | M | 71 | - | |
| Meredith Kaya | F | - | - | |
| Steven Mizell | M | 64 | 8 years | |
| Karen Akinsanya | M | 56 | 4 years | |
| Arnaub Chatterjee | M | - | 5 years | |
| Srikanth Venkatraman | M | - | 4 years | |
| Mark D. Plinio | M | 57 | 4 years | |
| Christopher Galloway | M | 53 | 2 years | |
| Reshma Rangwala | M | 46 | 5 years | |
| Yuan Xu | M | 56 | 2 years | |
| Ken Johnson | M | 61 | 1 years | |
| Joseph Eid | M | 56 | - | |
| Rongqiang Liu | M | 58 | 4 years | |
| Robert Plenge | M | 53 | 4 years | |
| Arthur Santora | M | 73 | 28 years | |
| Francesco Maria Lavino | M | 51 | 2 years | |
| Nancy Miller-Rich | F | 65 | 4 years | |
| Renu Vaish | F | - | 1 years | |
| Donald A. Fishbein | M | - |
Bausch Health US LLC
 Bausch Health US LLC Pharmaceuticals: MajorHealth Technology Bausch Health US LLC engages in the development, manufacture and market of pharmaceutical products. It specializes in therapeutic areas of neurology, dermatology, and infectious diseases. The company was founded in 2001 and is headquartered in Raleigh, NC. | 4 years |
| Mathai Mammen | M | 57 | 1 years | |
| Jonathan Robbins | M | - | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 49 | 89.09% |
| United Kingdom | 6 | 10.91% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew Davis
- Personal Network
